Skip to content

HYDEAL-D® Application for Promoting the Restoration of Sexual Function in the Postpartum Period

Randomized Clinical Trial to Assess the Efficacy and Safety of HYDEAL-D® Application in Promoting the Restoration of Sexual Function in the Postpartum Period

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04560283
Acronym
HYDEAL-D
Enrollment
25
Registered
2020-09-23
Start date
2016-09-01
Completion date
2020-09-01
Last updated
2023-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vagina; Anomaly, Puerperium; Disease, Sexual Dysfunction

Keywords

Puerperium

Brief summary

During postpartum and lactation, vaginal epithelium tends to have an impaired degree of hydration and lubrication. This may lead to vaginal dryness, burning sensation dyspareunia or itching, which negatively affect the sexual function of puerperal women. This study aimed to evaluate the efficacy of HYDEAL-D® vaginal gel (HYALOGYN®, Fidia Farmaceutici, Abano Terme, Italy) application on promoting the restoration of sexual function in the postpartum period.

Interventions

DRUGVaginal gel HYALOGYN®

Vaginal gel HYALOGYN® (HYDEAL-D® 2%; Fidia Farmaceutici, Abano Terme, Italy) every 3 days up for 12 consecutive weeks

Expectant management for 12 consecutive weeks

Sponsors

Ospedale Policlinico San Martino
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Women from 18 to 40 years old; * Women in the puerperium period (after vaginal delivery or cesarean section); * Women that are breast-feeding, that are not breast-feeding or that are breast-feeding partially;

Exclusion criteria

* Allergy to hyaluronic acid gel; * Women non-Italian speaking; * Women with signs of vaginal infection; * Women with a history of cancer of any site with recent genital bleeding of unknown origin; and patients with acute hepatopathy, embolic disorders, severe primary disease of kidney; * Women who are attending or have attended other clinical trials within previous two weeks; * Women with mental disorder and no insight

Design outcomes

Primary

MeasureTime frame
Evaluation of sexual function by FSFIAt baseline; 12 weeks

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026